Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 20/20 | 0.42 |
| ▸ | HSP90AB1 | P08238 | 20/20 | 0.42 |
| ▸ | HSP90B1 | P14625 | 1/20 | 0.40 |
| ▸ | TRAP1 | Q12931 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19236344 | 0.79 | HSP90AA1 (0.42) | HSP90AA1HSP90AB1HSP90B1TRAP1 | |
| SCHEMBL13477645 | 0.78 | HSP90AA1 (0.32) | HSP90AA1 | |
| SCHEMBL13477709 | 0.78 | MTNR1A (0.35) | HSP90AA1 | |
| SCHEMBL12634465 | 0.78 | HSP90AA1 (0.43) | HSP90AA1HSP90AB1HSP90B1TRAP1 | |
| SCHEMBL21644516 | 0.77 | HSP90AA1 (0.48) | HSP90AA1HSP90AB1HSP90B1TRAP1 | |
| SCHEMBL14106636 | 0.77 | HSP90AA1 (0.40) | HSP90AA1HSP90AB1 | |
| SCHEMBL21644562 | 0.75 | MET (0.58) | HSP90AA1HSP90AB1HSP90B1TRAP1 | |
| SCHEMBL14342524 | 0.74 | HSP90AA1 (0.37) | HSP90AA1HSP90AB1 | |
| SCHEMBL14106949 | 0.74 | HSP90AA1 (0.38) | HSP90AA1HSP90AB1 | |
| SCHEMBL16116986 | 0.73 | HSP90AA1 (0.40) | HSP90AA1HSP90AB1HSP90B1TRAP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013006864-A2 | TREATING CANCER WITH HSP90 INHIBITORY COMPOUNDS | SYNTA PHARMACEUTICALS CORP. (US) | 2013-01-10 | — | — | WO | disclosed |
| WO-2012155063-A1 | TREATING CANCER WITH AN HSP90 INHIBITORY COMPOUND | SYNTA PHARMACEUTICALS CORP. (US) | 2012-11-15 | — | — | WO | disclosed |